白蛋白结合型紫杉醇与溶剂型紫杉醇在卵巢癌新辅助化疗中的疗效分析

Analysis of the curative effect of albumin-bound paclitaxel and solvent paclitaxel in neoadjuvant chemotherapy for ovarian cancer.

目的对比白蛋白结合型紫杉醇和溶剂型紫杉醇在卵巢癌患者新辅助化疗过程中的疗效,以期为卵巢的治疗及预后提供依据。方法将2014年8月至2019年8月在哈尔滨医科大学附属肿瘤医院妇一科住院的208例卵巢癌患者随机分为白蛋白结合型紫杉醇组(104例)和溶剂型紫杉醇组(104例)。白蛋白结合型紫杉醇组给予白蛋白结合型注射用紫杉醇260mg/m^(2)静脉滴注治疗;溶剂型紫杉醇组卵巢癌患者则给予紫杉醇注射液175mg/m^(2)静脉滴注治疗。两组患者均连续治疗3个疗程,观察两组患者一般特征、随访结果、不良反应情况及卵巢癌标志物表达水平。结果白蛋白结合型紫杉醇组患者癌性腹水(65.4%vs.84.6%)和淋巴结转移(19.2%vs.34.6%)发生率、化疗前肿瘤相关标志物CA125(44.9%vs.55.1%)、肿瘤细胞增殖指数Ki67(29.5±20.16 vs.35.71±20.0)表达水平均低于溶剂型紫杉醇组患者(均P<0.05)。结论白蛋白结合型紫杉醇的疗效较好,不良反应发生率更低,更适合用于卵巢癌的新辅助化疗。

Objective To compare the efficacy of albumin-bound paclitaxel and solvent paclitaxel in neoadjuvant chemotherapy in patients with ovarian cancer,in order to provide evidence or ovarian treatment and prognosis.Methods The 208 patients with ovarian cancer who were hospitalized in the First Department of Gynecology,Harbin Medical University Cancer Hospital from August 2014 to August 2019 were randomly divided into albumin-bound paclitaxel group(104 cases)and solvent paclitaxel group(104 cases).The patients in the albumin-bound paclitaxel group were treated with albumin-bound paclitaxel for injection at 260mg/m^(2).The patients in the solvent paclitaxel group were treated with paclitaxel injection at 175mg/m^(2) intravenously.The patients in the two groups were treated for three consecutive courses.The general characteristics,follow-up results,adverse reactions and the expression level of ovarian cancer markers were observed.Results The incidence of cancerous ascites(65.4%vs.84.6%)and lymph node metastasis(19.2%vs.34.6%),and the expression level of pre-chemotherapy tumor-related marker CA125(44.9%vs.55.1%)and tumor cell proliferation index Ki67(29.520.16 vs.35.7120.0)in albumin-bound paclitaxel group was lower than that of patients in the solvent paclitaxel group(all P<0.05).Conclusion Albumin-bound paclitaxel has better curative effect and lower incidence of adverse reactions.It is more suitable for neoadjuvant chemotherapy for ovarian cancer.